Bioavailable Testosterone Predicts a Lower Risk of Alzheimer's Disease in Older Men
The DOI matches its Crossref record.
Abstract
There is a paucity of data on the relationship between testosterone and Alzheimer's disease (AD) in older men. The objective of the present study was to investigate the effects of serum total testosterone (TT), bioavailable testosterone (BT), and sex hormone binding globulin (SHBG) levels on the subsequent risk of AD in nondemented Chinese older men. This was a one-year prospective cohort study. 153 ambulatory community-living nondemented Chinese older men, aged 55 years or over, were recruited and followed for one year. Morning serum TT, BT, and SHBG levels were measured at baseline. At one-year of followup, assessment for dementia and AD were performed. AD was diagnosed by the NINCDS-ADRDA criteria for probable AD. Overall, the mean age of the subjects was 72.7 (SD 6.9). 6.5% (n = 10) developed dementia (converters), all having AD. 93.5% (n = 143) did not develop dementia (non-converters). Logistic regression analysis for independent predictors of AD showed that the baseline serum BT level, systolic blood pressure (SBP) and ApoE "4 genotype were significant independent predictors, after adjustment for age, education, BMI, fasting plasma glucose, and serum HDLC levels. The baseline serum BT level predicted a reduced risk of AD (adjusted relative risk (RR) 0.22, 95% CI: 0.07-0.69)). Baseline SBP and ApoE "4 genotype but not SHBG were independent risk factors, with RRs of 1.04 and 5.04 respectively. In conclusion, the serum level of bioavailable testosterone in late life predicts a lower risk of future AD development in older men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hersi, M., Irvine, B., Gupta, P., Gomes, J., Birkett, N., & Krewski, D. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.03.006 · Cited by 332
Testosterone Treatment of Men With Mild Cognitive Impairment and Low Testosterone Levels
Cherrier, M. M., Anderson, K., Shofer, J., Millard, S., & Matsumoto, A. M. (2015) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317514556874 · Cited by 71
Metadata
- Authors
- Chu, L.-W., Tam, S., Wong, R. L. C., Yik, P.-Y., Song, Y., Cheung, B. M. Y., Morley, J. E., & Lam, K. S. L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-09-10
- Volume
- 21
- Issue
- 4
- Pages
- 1335-1345
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2103130843
- Cited by
- 63
- References
- 0
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bioavailable Testosterone Predicts a Lower Risk of Alzheimer's Disease in Older Men. https://app.cochat.ai/papers/10.3233/jad-2010-100027
- The paper
- Chu, L.-W., Tam, S., Wong, R. L. C., Yik, P.-Y., Song, Y., Cheung, B. M. Y., Morley, J. E., & Lam, K. S. L. (2010). Bioavailable Testosterone Predicts a Lower Risk of Alzheimer's Disease in Older Men. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2010-100027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.